| Role | Headcount | Avg Salary | Annual Cost |
|---|
| Today | 10-Year | Source |
|---|
| Market | Size (2025) | Projected | CAGR | Source |
|---|---|---|---|---|
| US Dietary Supplements | $68.7B | $131B (2033) | 8.5% | Grand View Research |
| DTC Lab Testing (US) | $1.2B | $8.2B (2034) | 8.9% | Precedence Research |
| Digital Health (Global) | $347-427B | $574-946B (2030) | 17-24% | Fortune BI / Grand View |
| Health Coaching (Global) | $17.5B | $33.4B (2034) | 6.7% | Precedence Research |
| US Wellness (Total) | $935-989B | $1.55T (2033) | 5.7% | MarketDataForecast |
| Consumer Behavior | ||||
| US adults taking supplements | 70%+ | CRN Consumer Survey, 2023 | ||
| Wellness is "top priority" | 82-84% of US consumers | McKinsey Future of Wellness | ||
| Willing to spend $100+/mo on wellness | 55% of consumers | McKinsey Future of Wellness | ||
| Personalized health segment CAGR | 16.2% | MarketDataForecast (fastest-growing) | ||
Population
Target Segments
Monetization
10-Year Growth
| Company | Revenue | Users | ARPU | CAC | Capital Raised | Valuation | Growth | Model |
|---|---|---|---|---|---|---|---|---|
| Direct Comps — Health Testing & Longevity | ||||||||
| Function Health | $100M ARR | 200K | $365-500/yr | — | $350M | $2.5B | ~450% | Lab testing membership, 50M+ tests |
| Superpower | ~$18M est. | 150K waitlist | $199-499/yr | — | $34M | $300M+ | — | 100+ biomarkers + AI + concierge MD + supps marketplace, acquired Base (90K users) + Feminade (5K) |
| OneTwenty fka Outlive.bio | Beta | 25 beta | $499-1,499/yr | — | Pre-seed | — | — | Labs + wearables + AI coach + Rx + supplements, 10K waitlist |
| InsideTracker | N/A | N/A | $149-1,781/yr | — | $17.5M | ~$91M est. | — | Blood biomarkers + AI plans |
| Levels | ~$8M (2021) | 60K | $125-288/yr | — | $56M | $300M | — | CGM metabolic health, pivoting to software-first |
| Adjacent — Wearables & Subscriptions | ||||||||
| Oura | ~$1B | 2M subs | $55/yr sub | $50-80 | $1.3B | $11B | ~100% | Smart ring + $6/mo sub, 5.5M rings sold |
| Whoop | $260M+ | N/A | $199-359/yr | — | $801M | $3.6-9B | — | Wearable fitness, sub-only, IPO planned |
| Adjacent — Digital Health & DTC | ||||||||
| Hims & Hers NYSE: HIMS | $2.35B | 2.5M | $996/yr | ~$89 | Public | $3.5B mkt cap | 59% YoY | Telehealth + supps + Rx, 74% GM, 39% mktg/rev |
| Noom | ~$1B ARR | 1.5M paid | $667/yr | ~$10 affil. | $624M | $3.7B | ~25% | Health coaching + GLP-1 ($100M run-rate) |
| Ro | $598M ARR | N/A | N/A | — | $1.03B | $7B (2022) | 66% YoY | Digital health DTC, 40% rev from GLP-1s |
| Thorne L Catterton | $394M | 400K subs | N/A | $38 | $70M IPO | $680M acq. | ~30% | Premium supps + testing, LTV/CAC 4.6x |
| Benchmarks | ||||||||
| Median ARPU | $365-996/yr | Supports our $1,200 gross ARPU | ||||||
| CAC range | $38-89 | Thorne $38 (DTC supps), HIMS ~$89 (telehealth + Rx) | ||||||
| LTV/CAC ratio | 4-5x | HIMS ~4x, Thorne 4.6x | ||||||
| Revenue multiples | 1.5-25x | HIMS 1.5x (public) to Function 25x (high-growth) | ||||||
| Gross margins | 70-80% | HIMS 74%, sub models higher | ||||||